{"id":195086,"date":"2026-08-11T12:37:40","date_gmt":"2026-08-11T07:07:40","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=195086"},"modified":"2026-08-11T12:37:42","modified_gmt":"2026-08-11T07:07:42","slug":"gland-pharma-q1-results-fy27-pat-316-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/","title":{"rendered":"Gland Pharma Q1 FY27 Results: Revenue Rs 1,800 Cr, PAT Rs 316 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Gland Pharma Q1 FY27 results declared August 10, 2026. Revenue Rs 1,800 Cr (+19.57% YoY). PAT Rs 316 Cr (+47.09% YoY). CMP Rs 2667.3 (+2.55%).<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/gland\/gland-pharma-ltd-share-price-today\">Gland Pharma<\/a> Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +19.57% YoY to Rs 1,800 Cr from Rs 1,505 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 378 Cr (+41.77% YoY). PAT came in at Rs 316 Cr (+47.09% YoY), reflecting the key financial metrics of Gland Pharma Q1 FY27 results.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=gland-pharma-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Gland_Pharma_Q1_FY27_Financial_Highlights\" title=\"Gland Pharma Q1 FY27 Financial Highlights\">Gland Pharma Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Gland_Pharma_Q1_FY27_Performance_Analysis\" title=\"Gland Pharma Q1 FY27 Performance Analysis\">Gland Pharma Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Key_Business_Factors_in_Gland_Pharma_Q1_FY27_Results\" title=\"Key Business Factors in Gland Pharma Q1 FY27 Results\">Key Business Factors in Gland Pharma Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Revenue_Expansion_in_Q1_FY27\" title=\"Revenue Expansion in Q1 FY27\">Revenue Expansion in Q1 FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Operating_Margin_Performance\" title=\"Operating Margin Performance\">Operating Margin Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#PAT_Trajectory_and_Profitability\" title=\"PAT Trajectory and Profitability\">PAT Trajectory and Profitability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#FY27_Outlook_for_Gland_Pharma\" title=\"FY27 Outlook for Gland Pharma\">FY27 Outlook for Gland Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Gland_Pharma_Stock_Performance_After_Q1_FY27_Results\" title=\"Gland Pharma Stock Performance After Q1 FY27 Results\">Gland Pharma Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Key_Risks_for_Gland_Pharma\" title=\"Key Risks for Gland Pharma\">Key Risks for Gland Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Frequently_Asked_Questions_on_Gland_Pharma_Q1_FY27_Results\" title=\"Frequently Asked Questions on Gland Pharma Q1 FY27 Results\">Frequently Asked Questions on Gland Pharma Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#When_were_Gland_Pharma_Q1_FY27_results_declared\" title=\"When were Gland Pharma Q1 FY27 results declared?\">When were Gland Pharma Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#What_was_Gland_Pharma_revenue_in_Q1_FY27\" title=\"What was Gland Pharma revenue in Q1 FY27?\">What was Gland Pharma revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#What_was_Gland_Pharma_PAT_in_Q1_FY27\" title=\"What was Gland Pharma PAT in Q1 FY27?\">What was Gland Pharma PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#Did_Gland_Pharma_declare_a_dividend_in_Q1_FY27\" title=\"Did Gland Pharma declare a dividend in Q1 FY27?\">Did Gland Pharma declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#What_is_the_FY27_outlook_for_Gland_Pharma\" title=\"What is the FY27 outlook for Gland Pharma?\">What is the FY27 outlook for Gland Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-q1-results-fy27-pat-316-crore\/#How_did_Gland_Pharma_stock_react_to_Q1_FY27_results\" title=\"How did Gland Pharma stock react to Q1 FY27 results?\">How did Gland Pharma stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Gland_Pharma_Q1_FY27_Financial_Highlights\"><\/span><strong>Gland Pharma Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #fff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Gland Pharma Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">1,800<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">1,505<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+19.57%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">378<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">266<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+41.77%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">316<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">215<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+47.09%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Consolidated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Gland_Pharma_Q1_FY27_Performance_Analysis\"><\/span><strong>Gland Pharma Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Gland Pharma Q1 FY27 results reflect healthy fundamentals. Revenue momentum were evident with the top line reaching Rs 1,800 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit expanded +41.77% YoY. PAT of Rs 316 Cr reflects +47.09% YoY movement. Investors tracking Gland Pharma Q1 FY27 results will note these as key FY27 milestones.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Gland_Pharma_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Gland Pharma Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Expansion_in_Q1_FY27\"><\/span><strong>Revenue Expansion in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma Q1 FY27 results show revenue expanding +19.57% YoY to Rs 1,800 Cr from Rs 1,505 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Margin_Performance\"><\/span><strong>Operating Margin Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Gland Pharma Q1 FY27 results stood at Rs 378 Cr (+41.77% YoY). Better cost absorption and product mix improvement contributed to the operating performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Trajectory_and_Profitability\"><\/span><strong>PAT Trajectory and Profitability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT in Gland Pharma Q1 FY27 results was Rs 316 Cr (+47.09% YoY), reflecting the company&#8217;s improving financial health.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was declared alongside Gland Pharma Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Gland_Pharma\"><\/span><strong>FY27 Outlook for Gland Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gland Pharma is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Gland Pharma Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Gland_Pharma_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Gland Pharma Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Gland Pharma live price and get daily stock recommendations.<\/em><\/p>\n<p>Gland Pharma shares were trading higher at Rs 2667.3 (+2.55%) on August 10, 2026, reflecting investor sentiment on Gland Pharma Q1 FY27 results and the near-term sector outlook. The CMP of Rs 2667.3 on the results date reflects broader sentiment toward the pharmaceuticals space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Gland_Pharma\"><\/span><strong>Key Risks for Gland Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gland Pharma Q1 FY27 results reflect healthy performance with revenue at Rs 1,800 Cr and PAT at Rs 316 Cr on a Consolidated basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Gland_Pharma_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Gland Pharma Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Gland_Pharma_Q1_FY27_results_declared\"><\/span><strong>When were Gland Pharma Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gland Pharma Q1 FY27 results were declared on August 10, 2026, covering the April\u2013June 2026 quarter on a Consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Gland_Pharma_revenue_in_Q1_FY27\"><\/span><strong>What was Gland Pharma revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in Gland Pharma Q1 FY27 results was Rs 1,800 Cr, +19.57% YoY from Rs 1,505 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Gland_Pharma_PAT_in_Q1_FY27\"><\/span><strong>What was Gland Pharma PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Gland Pharma Q1 FY27 results was Rs 316 Cr (+47.09% YoY).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Gland_Pharma_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Gland Pharma declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside Gland Pharma Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Gland_Pharma\"><\/span><strong>What is the FY27 outlook for Gland Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Gland_Pharma_stock_react_to_Q1_FY27_results\"><\/span><strong>How did Gland Pharma stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gland Pharma shares were higher at Rs 2667.3 (+2.55%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma Q1 FY27 results: Revenue Rs 1,800 Cr (+19.57% YoY), PAT Rs 316 Cr (+47.09% YoY). Key highlights, analysis and FY27 outlook.<\/p>\n","protected":false},"author":35,"featured_media":195085,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-195086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["195085"],"_edit_lock":["1786432064:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Gland Pharma Q1 FY27 Results: Revenue, PAT &amp; Key Highlights"],"rank_math_description":["Gland Pharma Q1 FY27 results: Revenue Rs 1,800 Cr (+19.57% YoY), PAT Rs 316 Cr (+47.09% YoY). Key highlights, analysis and FY27 outlook."],"rank_math_focus_keyword":["Gland Pharma Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35846"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/gland-pharma-q1-results-fy27-pat-316-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=195086"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195086\/revisions"}],"predecessor-version":[{"id":196530,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195086\/revisions\/196530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/195085"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=195086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=195086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=195086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}